Double mutations in the quinolone resistance determining region of the gyrase A gene (gyrA) have recently been reported to be associated with high-level resistance to fluoroquinolones in clinical isolates of Escherichia coli. We examined the type and frequency of such mutations in a large number of clinical isolates that were obtained from ten different geographical locations and had been genotypically characterized by pulsed field gel electrophoresis (PFGE) of chromosomal DNA digests. Of 36 isolates with ofloxacin MICs ;>4 mg/L that represented at least 24 distinct genotypes, 35 had double mutations at amino acid codons 83 and 87 of gyrA, while two isolates with ofloxacin MICs of 0.5 and 4 mg/L, respectively, each had a single mutation at codon 83. Mutations at codon Ser-83 were uniform, resulting in substitution by Leu. The additional mutations at amino acid codon 87 in the 35 double-mutants were diverse, resulting in Asp-87 substitutions by residues Asn (23 isolates), Gly (7 isolates), Tyr (4 isolates), or His (1 isolate) without a discernable correlation with fluoroquinolone MICs or with phenotypic resistance to chemically unrelated antibacterial agents. Maximal differences between MICs of double-mutants with the same amino acid substitution were eight-fold. The changes of amino acid residues at codon Asp-87 differed between individual patient isolates with the same genotype (and similar MICs), suggesting that the amino acid codon 87 mutations (and possibly the development of high-level fluoroquinolone resistance) might have occurred after the transmission and sharing of a precursor strain carrying the Ser-83 -> Leu mutation.
Introduction
Fluoroquinolones are low-molecular weight synthetic bactericidal agents with a particular activity against Gram-negative bacilli (Hooper & Wolfson, 1985) . Bacterial resistance to fluoroquinolones has been observed infrequently among members of the Enterobacteriaceae family. Case reports of resistance to fluoroquinolones in Escherichia coli clinical isolates appeared in the mid 1980s (Sato et al., 1986; Aoyama et al., 1987; Lewin et al., 1988; Jonsson, Walder & Forsgren, 1990; Lopez-Brea & Alarcon, 1990) , but in large studies, rates of resistance to fluoroquinolones among E. coli remained low for some years despite the excessive use of the agents both within hospitals and in the community (Kresken & Wiedemann, 1988; Kresken et al., 1994) . In recent years, there has been a number of studies showing a definite increase in rates of resistance among E. coli clinical isolates (Rodriguez-Creixems et al., 1991; Arduino et al., 1992; Lopez-Brea et al., 1992; Alarcon et al., 1993; Mirelis et al., 1993; Navarro et al., 1993; Perez-Trallero et al., 1993; Cometta et al., 1994; Kern et al., 1994a; Carratala et al., 1995) . This is of particular concern since fluoroquinolone agents have been recommended for therapy or prophylaxis in clinical situations where E. coli is one of the leading bacterial pathogens, such as urinary tract infection or fever during granulocytopenia.
Mechanisms of bacterial resistance to fluoroquinolones include chromosomal mutations that alter DNA gyrase, the cellular target of the drugs, or reduce intracellular drug concentration. A number of genes associated with quinolone resistance have been identified in E. coli. These include gyrA and gyrB that encode DNA gyrase. Mutants with resistance to nalidixic acid typically carry a mutation at amino acid codon Ser-83 in the so-called quinolone resistance determining region (QRDR) of gyrA while gyrB mutations are rare, both among laboratory and clinical strains (Cullen et al., 1989; Nakamura et al., 1989; Yoshida et al., 1990; Oram & Fisher, 1991) . Mutations at Ser-83 have been associated with reduced binding of the fluoroquinolone agents to DNA gyrase-DNA complexes (Willmott & Maxwell, 1993) and, consequently, with reduced inhibition of DNA supercoiling. Mutants with the Ser-83 mutation are highly resistant to nalidixic acid and show decreased susceptibility, but usually no clinical resistance, to fluoroquinolones. Unlike these mutants, however, many of the clinical isolates of E. coli now show high-level resistance not only to nalidixic acid, but also to fluorinated quinolones. One or more additional mutation(s) are thought to play a role for the expression of high-level resistance in these isolates. Recently, double mutations in the QRDR of gyrA have been identified among clinical E. coli isolates with varying MICs of ciprofloxacin (Heisig, Schedlitzky & Falkenstein-Paul, 1993; Soussy et al., 1994; Vila et al., 1994) . The type and frequency of such mutations among epidemiologically and genetically unrelated fluoroquinolone-resistant isolates from different geographical regions, however, have not been determined.
In the present study, we used 36 clinical isolates of E. coli from ten different locations across Europe and the Middle East that represented at least 24 distinct genotypes to analyse, by PCR and direct DNA sequencing, the gyrA mutations associated with high-level fluoroquinolone resistance.
Material and methods

Bacterial isolates
A total of 36 fluoroquinolone-resistant clinical isolates of E. coli, selected from a previously reported collection of 58 isolates characterized by genotyping and antimicrobial susceptibility (Oethinger et al., 1995) were studied. Those selected for this study included (i) 21 fluoroquinolone-resistant isolates, designated E strains, that were cultured from blood of cancer patients admitted to different cancer centres across Europe and the Middle East and included in the two most recent clinical trials (trials IX and XI) of the European Organization for Research and Treatment of Cancer (EORTC) International Antimicrobial Therapy Cooperative Group EORTC International Antimicrobial Therapy Cooperative Group & GIMEMA Infection Program, 1995) ; (ii) nine of 16 blood culture isolates obtained from individual patients admitted to the haematology-oncology service of Ulm University Hospital, designated HO strains; and (iii) six of 21 quinolone-resistant isolates of E. coli obtained from individual patients admitted to surgical services of Ulm University Hospital, designated NH strains.
Four selected fluoroquinolone-susceptible clinical isolates from patients with bacteraemia admitted to Ulm University Hospital, designated S strains, and E. coli ATCC 25922 were used as controls.
Stock cultures were kept frozen at -70°C using the Microbank system (Mast, Reinfeld, Germany). The isolates were identified as E. coli by standard methods (Farmer & Kelly, 1991) including biochemical reactions in the API 20 E reaction profile (Biomerieux, Nurtingen, Germany).
MICs of selected antimicrobial agents were determined by a standard broth microdilution procedure with cation-adjusted Mueller-Hinton broth and a final inoculum of 5 x KPcfu/mL according to NCCLS performance and interpretive guidelines (NCCLS, 1990) . Microtitre plates were purchased from Merlin Diagnostics (Bornheim, Germany).
All fluoroquinolone-resistant isolates had a MIC of ofloxacin >4mg/L with complete cross-resistance to other fluoroquinolones, and many were resistant to several antimicrobial agents of unrelated chemical classes (Oethinger et al., 1995) .
All isolates had been subjected to genotyping by pulsed field gel electrophoresis (PFGE) of chromosomal DNA digests, performed according to Linhardt et al. (1992) with minor modifications (Oethinger et al., 1995) . Briefly, DNA from lysed bacterial cells was isolated in agarose plugs. After removal of proteins, the plugs were equilibrated in restriction enzyme buffer, and the genomic DNA was digested with Xba\ or Notl. Electrophoresis was performed in 1% agarose gels at 12°C in a Rotaphore Type IV (Biometra, Gottingen, Germany). Constant voltage of 240 V was applied with an increasing pulse time of 5-35 sec over a period of 18 h after starting conditions of 5 sec pulse time for 4 h. Gels were stained with ethidium bromide and photographed under UV light. Based on the macrorestriction fragment patterns, similarity values were calculated and dendrograms for cluster analysis were constructed using the Diversity One software (pdi Inc., Huntington Station, USA). Genotypes were defined on the basis of a common macrorestriction pattern showing a similarity of ;>90%. The Figure shows the similarity of the isolates. Among the 21 E isolates, all 14 isolates typeable by PFGE were unrelated to each other ( Figure) , whereas among the 16 HO isolates, the 13 typeable isolates were grouped into five Xba\ ( Figure) or Notl (data not shown) genomic clusters (designated A, B, C, D, E) . At least one isolate from each cluster was used for DNA sequencing studies of the gyrA QRDR in the present study (Figure and  Table) .
Genotyping of the NH and S E. coli clinical isolates revealed that they were unrelated to each other as well as to E and HO strains (Oethinger et al., 1995) , except for one NH strain (NH11) that was untypeable.
DNA amplification and sequencing
A single colony was suspended in 50 /iL NaOH (50mM) and boiled for 10 min to prepare templates for PCR. The culture was neutralized with 8 /iL Tris-HCl, pH 7 (1 M), diluted ten-fold in distilled water, and used either immediately or stored at -20°C until needed. The 20-and 19mer primers were as described by Oram & Fisher (1991) , starting at nucleotide 24 (5'-TACACCGGTCAACATTGAGG-3') and nucleotide 671 (5'-TTAATGATTGCCGCCTCGG-3'), respectively. They were synthesized on a 381A DNA synthesizer (Applied Biosystems, Weiterstadt, Germany).
PCR was carried out in a volume of 100 /iL containing 2.5 U of AmpliTaq polymerase (Applied Biosystems), standard PCR buffer (10 mM Tris-HCl, pH 8.3, 50 mM KC1, 1.5 mM MgCh, 0.01% gelatin, 200//M of each dNTPs (Boehringer, Mannheim, Germany) lOpmol of each primer and 10/iL of the 1/10 dilution of boiled E. coli colony. The reaction was performed in a thermal cycler programmed for denaturation at 96°C for 4 min, and 30 cycles as follows: 94°C for 30 sec and 63°C for 2.5 min. The final extension was allowed at 72°C for 5 min. Ten microlitres of products were electrophoresed on a 2% NuSieve agarose gel (Biozym, Hameln, Germany) to ensure homogeneity and to assess the yield. Contamination was avoided by using three separate rooms for mixing reaction solutions, DNA preparations and amplification, respectively.
PCR-amplified DNA was purified using Qiaquick spin PCR purification kit (Diagen, Hilden, Germany) according to the manufacturer's instructions. Dendrograms indicating the genotypic similarity or diversity of high-level fluoroquinolone-resistant clinical isolates of E. coli according to PFGE of chromosomal DNA digested with Xba\. Left: HO isolates; the 13 typeable isolates clustered into five PFGE genotypes (A, B, C, D, and E) of which four were shared by several patients; the 9 HO isolates were examined for gyrA mutations in this study. Right: E isolates; 14 typeable isolates were unrelated to each other. 
'PFGE, pulsed field gel electrophoresis; nt, nontypeable; PFGE genotypes are only indicated if strains were shared by patients 'Nal, Naliduuc acid, Tsx, tnmethopnm-sulphamethoxazole, Amp, ampicillin; Tet, tetracyclme; Oil, chloramphenicol; Gen, gentamicin, MICs of nahdixic acid were 128 mg/L for strain S14, and > 1024 mg/L for all remaining nalidixic acid-resistant isolates.
(5'-ATTGTTGGCCGTGCGCTGCCAGAT-3') and at nucleotide 369 of the gyrA gene with primer ECGYRA:535 (5'-GTATAACGCATTGCCGC-3) for the complemetary DNA strand of the gyr A gene. Asymmetric amplifications were carried out under the following conditions: denaturation at 96°C, 4 min; 25 cycles were run at 94°C, 30 sec and 63°C, 4 min. The sequences were tested in both directions and with additional independent reactions at different times to check for contamination and errors introduced during PCR. Nucleotide sequences were determined in an automatic 373A DNA Sequencer (Applied Biosystems).
Results
A total of 36 fluoroquinolone-resistant isolates from ten different geographical locations were studied representing at least 24 different PFGE genotypes. The MICs of ofloxacin for the isolates ranged from <;0.06 to 0.5 mg/L for the susceptible control strains, and from 4 to 64 mg/L for the resistant isolates (Table) . MICs of ciprofloxacin in the resistant isolates ranged from 2 to 128 mg/L (data not shown), and those of nalidixic acid were > 1024 mg/L. It should be noted that the patients from whom the isolates were obtained had been treated with various fluoroquinolones. The Table lists the MICs of ofloxacin only, in order to rank the relative resistances of the isolates.
A DNA fragment of 648 bp, from nucleotide 24 to 671 of gyr A, was obtained by PCR, as expected. DNA sequencing of the purified PCR products and comparison of the results between nucleotides 123 to 366 (Leu-41 to Tyr-122) of gyr A with the known DNA sequence of the E. coli K-12 gyr A gene (Swanberg & Wang, 1987) showed nucleotide changes at amino acid codons 83, 85, 87, 89, 91, 100 and 111. All susceptible and resistant isolates and E. coli ATCC 25922 had the nucleotide transition T-to-C at codon Ile-89 that was also described by Heisig el al. (1993) , Ouabdesselam et al. (1995) and Oram & Fisher (1991) . Other silent mutations were inconsistently observed among both susceptible and resistant isolates. These included C-to-T transitions at codons 85, 100 and 111, and a T-to-C transition at codon 91 (Table) . The C-to-T transition at codon 85 has also been described by Heisig et al. (1993) , Ouabdesselam et al. (1995) and Oram & Fisher (1991) .
Mutations leading to amino acid substitutions were observed at codons 83 and 87 and are shown in the Table. All 37 nalidixic acid-resistant isolates, irrespective of their fluoroquinolone MICs, carried the C-to-T transition at codon 83 leading to the Ser-83->Leu change. Two isolates (SI4 and NH40) had the mutation Ser-83-+Leu alone (Table) . These isolates had ofloxacin MICs of 0.5 and 4 mg/L, respectively. In contrast, all 35 resistant isolates with ofloxacin MICs >4 mg/L included in this study had double mutations in the QRDR of gyrA. The additional mutations at codon Asp-87 in these 35 isolates included amino acid substitutions by Asn (23 isolates), Gly (seven isolates), Tyr (four isolates), or His (one isolate) without a discernable correlation with fluoroquinolone MICs (Table) . The frequent Asp-87-»Asn change, for example, was found in isolates with ofloxacin MICs ranging from 8 to 64 mg/L. Also, there was no apparent association between resistance to chemically-unrelated antimicrobial agents and gyrA mutations.
Resistant isolates that appeared genetically related or indistinguishable by PFGE genotyping did not necessarily carry the same point (or silent) mutation. Isolates belonging to genotype A (strains HOI, HO3, and HO5) or genotype C (strains HO6, HOI3, and HO4) had either the Asp-87-»Asn or the Asp-87->Gly change (Table) .
Discussion
Many of the gyrA mutations found in this study have been described previously. The Ser-83-*Leu mutation has been identified in several laboratory and clinical isolates of E. coli (Yoshida et al., 1988; Cullen et al., 1989; Yoshida et al., 1990; Oram & Fisher, 1991) . Similar mutations at the corresponding amino acid codons have been found in a variety of bacteria including staphylococci, mycobacteria, Pseudomonas aeruginosa, species of Salmonella, Shigella, and Neisseria, Acinetobacter baumannii and Campylobacter jejuni (Sreedharan et al., 1990; Goswitz et al., 1992; Wang, Huang & Taylor, 1993; Ito et al., 1994; Kureishi et al., 1994; Rahman et al., 1994; Reyna et al., 1995; Takenouchi et al., 1995; Vila et al., 1995; Yasuda et al., 1995) . In E. coli, the level of resistance to fluoroquinolones in these mutants appears rather low with MICs of ciprofloxacin ranging from 0.08 (Soussy et al., 1994) to 4 mg/L (Vila et al., 1994) . Our finding of ofloxacin MICs of 0.5 and 4 mg/L (and ciprofloxacin MICs of 0.12 and 2 mg/L, respectively) in the two Ser-83->Leu single mutants in the present study is consistent with these earlier observations.
In contrast to a recent study by Ouabdesselam et al. (1995) , but in common with the findings of Vila et al. (1994) , we did not find isolates with a single mutation at amino acid codon 87. The level of resistance in the few reported isolates of E. coli and, recently, of Salmonella and Campylobacter spp. with such a mutation also appears to be rather low. Ciprofloxacin MICs of ^4 mg/L have been reported in isolates carrying the Asp-87->Gly change (Ouabdesselam et al., 1995) , and MICs of ciprofloxacin werê 0.25 mg/L in isolates carrying an Asp-87-»Val or Asp-87-»Asn single mutation (Yoshida et al., 1988; Oram & Fisher, 1991; Wang et al., 1993; Reyna et al., 1995) . Obviously, a much larger collection of isolates specifically with low-level resistance would be needed to assess in detail the types and frequencies of single mutations at codon 87 in clinical isolates.
It was interesting to note that residues at codon 87 in our isolates were variable, while the mutation at codon 83 was uniformly Ser-83 ->Leu. This corroborates and extends the results of Vila et al. (1994) who reported double mutations Ser-83 -> Leu plus either Asp-87-* Tyr or Asp-87-* Asn in a number of fluoroquinolone-resistant urinary tract infection isolates from a single centre. The double mutation Ser-83-* Leu plus Asp-87->Gly has previously been identified by Heisig et al. (1993) in a clinical E. coli isolate with a particularly high ciprofloxacin MIC (128 mg/L), and, more recently, by Soussy et al. (1994) in a clinical isolate with a ciprofloxacin MIC of 0.5 mg/L. This wide range of MICs in different isolates with the same gyrA mutations at codons 83 and 87 was also seen in the present study and by Vila et al. (1994) indicating substantial differences between isolates that are probably related to additional changes occurring during the development of fluoroquinolone resistance. Wide variation of fluoroquinolone MICs in isolates with the same gyrA mutation has also been reported in other bacterial species such as A. baumannii (Vila et al., 1995) and staphylococci (Takenouchi et al., 1995) .
The striking variability in residues at codon 87 has been reported for other species also. In mycobacteria, for example, changes to Asn, His, Gly, Tyr and Ala residues have been observed whereas Ala-83 (corresponding to Ser-83 in E. coli) point mutations have only included-*Val (Cambau et al., 1994; Takiff et al., 1994; Alangaden et al., 1995) . Similarly, in P. aeruginosa Thr-83 (corresponding to Ser-83 in E. coli) mutations include only-*Ile, while Asp-87 mutations in this species have included-*Asn, Gly, His, (Yonezawa et al., 1995) , and Tyr (Kureishi et al., 1994) . Thus, the Asp-87-*His mutation, observed in this study, although to the best of our knowledge, not identified previously in E. coli, is not entirely new (Cambau et al., 1994; Takiff et al., 1994; Yonezawa et al., 1995) . A certain variability was also noted with respect to third nucleotides (C-*T transitions and T->C transitions) in five codons of the QRDR. Similar silent nucleotide changes in E. coli have been reported earlier (Yoshida et al., 1988; Oram & Fisher, 1991; Heisig et al., 1993) . The significance of these nucleotide changes within the QRDR is presently unclear; they may be related to codon usage, and do not appear to be associated with particular levels of susceptibility or resistance to fluoroquinolones. Heisig & Tschorny (1994) recently showed in in-vitro experiments that the mutation Ser-83->Leu occurred as a first step in E. coli, while the change Asp-87-*Gly occurred in a second step. A similar sequence of events in vivo has been suggested by Soussy et al. (1994) after analysis of a pair of E. coli clinical isolates. These observations and the finding in the present and other studies of almost uniform changes at codon 83 with a much larger variability of residues at codon 87, argue in favour of a mutation at codon 83 as the primary, or at least an early event in the course of development of clinical resistance. Additional mutations leading to different residues at codon 87 (Asn-87 or Gly-87) in a gyrA single mutant may lead to similar fluoroquinolone MICs, as shown here for isolates of the same PFGE genotype A or C, and the diversity of residues at codon 87 may illustrate the ease at which Ser-83 -*Leu low-level resistant mutants mutate to high-level resistance. However, the earlier description of isolates bearing mutations of Asp-87 (or other positions) in the absence of mutations at Ser-83 suggests alternative pathways to high-level resistance. Also, it remains to be determined whether the finding of two different mutations at codon 87 in genotypically indistinguishable or closely-related isolates from different individuals indicates that shared strains might have been transmitted between patients before the second mutation occurred.
In view of the accumulating evidence that single mutations at either codon 83 or 87 usually confer a lesser degree of resistance to fluoroquinolones in a variety of microorganisms including E. coli, the frequent association of high-level resistance with gyrA double mutations in this collection of epidemiologically and genetically-unrelated E. coli clinical isolates is remarkable, but was not unexpected. In the vast majority of cases so far, clinical isolates have been cultured during or shortly after therapy with a fluoroquinolone (Kern et al., 1994a; Richard et al., 1994; Pefia et al., 1995) . gyrA single mutants with low-level resistance would be much less likely to survive at clinically achievable concentrations of a fluoroquinolone than double mutants with high-level resistance.
The association of high-level fluoroquinolone resistance in clinical isolates of E. coli and in other bacterial species with double mutations in the QRDR of gyrA requires further analysis. Two of the isolates included in this study (HOI and HO2) have earlier been shown to have a greatly reduced sensitivity of their DNA gyrase protein to fluoroquinolones (but normal susceptibility to novobiocin) without clearcut evidence of a significant permeability alteration (Kern, Markus & Andriof, 1994ft) . These two isolates, both of which carry gyrA double mutations (Ser-83-»Leu and Asp-87-»Tyr or Asp-87->Gly, respectively), closely resemble the high-level resistant clinical isolate characterized by Heisig et al. (1993) suggesting an important role for the gyrA double mutation in the observed high-level resistance in clinical isolates.
It is now clear, however, that fluoroquinolone MICs of isolates carrying the same double mutation, may vary widely. Although the exact role of the different types of gyrA double mutations has not yet been defined, mechanisms other than gyrA mutations with altered DNA gyrase subunit A are most likely to account for the wide range of MICs observed. Additional gyrB mutations might be an explanation, but they have only rarely been found among clinical isolates. Nakamura et al. (1989) found that one out of eight resistant isolates had a gyrB mutation. Similarly, Vila et al. (1994) found only one gyrB mutant among 14 high-level resistant clinical isolates, while in other studies there was no evidence for such a mutation (Heisige et al., 1993; Ouabdesselam et al., 1995) . Alternative hypotheses that need to be explored include the possibility of subtle differences in cell wall permeability and intracellular drug concentration. Based on recent work (Hoshino et al., 1994; Ferrero, Cameron & Crouzet, 1995; Khodursky, Zechiedrich & Cozzarelli, 1995) , however, other alterations, in particular mutations affecting the sensitivity to quinolones of topoisomerase IV in gyrA mutants appear to be the most likely to contribute to the observed high-level fluoroquinolone resistance.
